Compare Enveric Biosciences Inc (ENVB) vs Nano Dimension Ltd - ADR (NNDM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Nano Dimension Ltd - ADR — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Nano Dimension Ltd - ADR trades at $1.56 (market cap $328.52M). The key difference: Nano Dimension Ltd - ADR is far larger — about 48.3× Enveric Biosciences Inc's market cap, and Nano Dimension Ltd - ADR is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Nano Dimension Ltd - ADR for 43 Days on average.
| ENVB | NNDM | |
|---|---|---|
Market Cap | $6.80M | $328.52M |
Volume | 64,867 | 1,160,945 |
Sector | Health | Technology |
52-Week High | $10.80 | $2.14 |
52-Week Low | $1.27 | $1.21 |
Typical Hold Time | 14 Days | 43 Days |
Enterprise Value | -$1.49M | -$76.33M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
NNDM trades at $1.55, down 1.27% with bearish technical signals. The company shows revenue growth from $102M in 2025 to $121M in 2026 but continues to post significant losses with a -135.18% net income margin. Recent strategic moves include cost-cutting initiatives and leadership changes aimed at reducing cash burn. The stock faces headwinds from negative cash flow trends and persistent unprofitability despite improving sales.
Outlook remains challenging with substantial execution risks. The company's cash position of $758M provides runway, but continued losses and negative operating cash flow pose sustainability concerns. Investment opportunity exists if cost reductions translate to profitability, but high risk profile requires careful monitoring of quarterly execution against guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →
